IL134378A - קומפלקס מנוטרל מטען של אפרוסרטן ארגיניל, הכנתו ותכשירי רוקחות המכילים אותו - Google Patents

קומפלקס מנוטרל מטען של אפרוסרטן ארגיניל, הכנתו ותכשירי רוקחות המכילים אותו

Info

Publication number
IL134378A
IL134378A IL13437898A IL13437898A IL134378A IL 134378 A IL134378 A IL 134378A IL 13437898 A IL13437898 A IL 13437898A IL 13437898 A IL13437898 A IL 13437898A IL 134378 A IL134378 A IL 134378A
Authority
IL
Israel
Prior art keywords
composition according
compound
medicament
pharmaceutical composition
diuretic
Prior art date
Application number
IL13437898A
Other languages
English (en)
Other versions
IL134378A0 (en
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of IL134378A0 publication Critical patent/IL134378A0/xx
Publication of IL134378A publication Critical patent/IL134378A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
IL13437898A 1997-08-06 1998-08-04 קומפלקס מנוטרל מטען של אפרוסרטן ארגיניל, הכנתו ותכשירי רוקחות המכילים אותו IL134378A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5499097P 1997-08-06 1997-08-06
PCT/US1998/016245 WO1999007365A1 (en) 1997-08-06 1998-08-04 Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation

Publications (2)

Publication Number Publication Date
IL134378A0 IL134378A0 (en) 2001-04-30
IL134378A true IL134378A (he) 2004-02-19

Family

ID=21994861

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13437898A IL134378A (he) 1997-08-06 1998-08-04 קומפלקס מנוטרל מטען של אפרוסרטן ארגיניל, הכנתו ותכשירי רוקחות המכילים אותו

Country Status (27)

Country Link
EP (1) EP1027047B1 (he)
JP (1) JP4463975B2 (he)
KR (1) KR100508044B1 (he)
CN (1) CN1276724A (he)
AR (1) AR015930A1 (he)
AT (1) ATE341325T1 (he)
AU (1) AU739295B2 (he)
BR (1) BR9811926A (he)
CA (1) CA2299470C (he)
CO (1) CO4960666A1 (he)
CY (1) CY1105851T1 (he)
CZ (1) CZ296274B6 (he)
DE (1) DE69836095T2 (he)
DK (1) DK1027047T3 (he)
ES (1) ES2273433T3 (he)
HK (1) HK1031688A1 (he)
HU (1) HUP0201624A3 (he)
IL (1) IL134378A (he)
NO (1) NO317771B1 (he)
NZ (1) NZ502644A (he)
PL (1) PL198875B1 (he)
PT (1) PT1027047E (he)
SA (1) SA98190592B1 (he)
TR (1) TR200000350T2 (he)
TW (1) TW570921B (he)
WO (1) WO1999007365A1 (he)
ZA (1) ZA987018B (he)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
EP1197223B1 (en) * 1999-04-28 2005-02-16 Takeda Pharmaceutical Company Limited Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy
BRPI0406987A (pt) 2003-01-31 2006-01-10 Sankyo Co Medicamento para a prevenção e/ou tratamento de arteriosclerose, medicamentos para a inibição de proliferação de células do músculo liso vascular, de formação de neoìntima dos vasos sanguìneos e de remodelação vascular, medicamento para a prevenção de restenose que segue intervenção coronária percutânea, e, medicamentos para a profilaxia e/ou tratamento de hipertensão ou doenças causadas por hipertensão ou doenças causadas por hipertensão, de doenças cardìacas, de angina do peito, de infarto miocárdico, de arritmia, de morte súbita, de insuficiência cardìaca, de hipertrofia cardìaca, de doenças renais, de nefropatia diabética, de glomerulonefrite, de nefrosclerose, de doenças cerebrovasculares, de infarto cerebral, e de hemorragia cerebral
NO323391B1 (no) 2005-09-28 2007-04-23 Hts Hans Torgersen & Sonn As Barnepose
EP2167047A2 (en) * 2007-06-06 2010-03-31 Dexcel Ltd. Process for forming solid oral dosage forms of angiotensin ii receptor antagonists
JP5476782B2 (ja) * 2009-04-21 2014-04-23 大正製薬株式会社 アルギニン含有錠剤の製造方法
JP5446716B2 (ja) * 2009-10-21 2014-03-19 大正製薬株式会社 アルギニン及びカルニチン含有錠剤の製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
NZ239161A (en) * 1990-07-31 1994-01-26 Smithkline Beecham Corp Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,
DE69131021T2 (de) * 1990-12-14 1999-08-12 Smithkline Beecham Corp Angiotensin-ii-rezeptor blockierende zusammensetzungen
JP3214856B2 (ja) * 1990-12-14 2001-10-02 スミスクライン・ビーチャム・コーポレイション イミダゾリル−アルケン酸
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
DE4208052A1 (de) * 1992-03-13 1993-09-16 Bayer Ag Imidazolyl substituierte phenylessigsaeureamide
FR2688781B1 (fr) * 1992-03-23 1994-07-01 Sanofi Elf Imidazolines n-substituees par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
DE4210787A1 (de) * 1992-04-01 1993-10-07 Bayer Ag Cycloalkyl- und Heterocyclyl substituierte Imidazolylpropensäurederivate
JPH0841053A (ja) * 1994-07-28 1996-02-13 Nkk Corp ヘテロアリールアルキル基を有するピリミジン誘導体及 び該誘導体を有効成分として含有するアンジオテンシン ｉｉ拮抗剤
US5645839A (en) * 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
WO1997021707A1 (en) * 1995-12-14 1997-06-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone

Also Published As

Publication number Publication date
EP1027047A4 (en) 2002-09-18
CZ296274B6 (cs) 2006-02-15
TR200000350T2 (tr) 2000-12-21
JP4463975B2 (ja) 2010-05-19
WO1999007365A1 (en) 1999-02-18
CY1105851T1 (el) 2011-02-02
EP1027047B1 (en) 2006-10-04
JP2001513498A (ja) 2001-09-04
IL134378A0 (en) 2001-04-30
AU739295B2 (en) 2001-10-11
BR9811926A (pt) 2000-08-22
NO20000577D0 (no) 2000-02-04
AU8768898A (en) 1999-03-01
CZ2000406A3 (cs) 2000-09-13
NO317771B1 (no) 2004-12-13
HUP0201624A2 (hu) 2002-12-28
ES2273433T3 (es) 2007-05-01
CA2299470C (en) 2010-01-26
NZ502644A (en) 2002-03-01
PL198875B1 (pl) 2008-07-31
DE69836095D1 (de) 2006-11-16
CO4960666A1 (es) 2000-09-25
HUP0201624A3 (en) 2003-03-28
CA2299470A1 (en) 1999-02-18
KR100508044B1 (ko) 2005-08-17
DE69836095T2 (de) 2007-04-12
ATE341325T1 (de) 2006-10-15
PT1027047E (pt) 2007-01-31
EP1027047A1 (en) 2000-08-16
AR015930A1 (es) 2001-05-30
HK1031688A1 (en) 2001-06-22
KR20010022582A (ko) 2001-03-26
TW570921B (en) 2004-01-11
DK1027047T3 (da) 2007-01-29
SA98190592B1 (ar) 2006-06-20
NO20000577L (no) 2000-02-29
ZA987018B (en) 1999-02-08
PL341562A1 (en) 2001-04-23
CN1276724A (zh) 2000-12-13

Similar Documents

Publication Publication Date Title
US6630498B2 (en) Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation
AU763309B2 (en) Bioenhanced formulations comprising eprosartan in oral solid dosage form
US6558699B2 (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
AU750611B2 (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
CA2299470C (en) Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation
MXPA00001385A (en) Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation
MXPA00004791A (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
CZ20001802A3 (cs) Orální dávkové prostředky s okamžitým nebo modifikovaným uvolňováním vysoké náplně léčiva a způsoby jejich přípravy
CZ2001227A3 (cs) Biologicky zlepšené prostředky obsahující eprosartan v orální pevné dávkové formě

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees